09.15.20

European Medicines Agency (EMA) Approves Safety Label Update for Novartis’ Beovu

Source: Novartis

09.14.20

Novartis Reports Topline Results From the First Phase 3 Trial of Beovu Versus Aflibercept in DME Patients

Source: Novartis

07.27.20

New Novartis Analysis Examines Sustainable Fluid Control of Beovu Compared With Aflibercept

Source: Novartis

06.08.20

Novartis Provides Update On Use and Safety of Beovu (brolucizumab)

Source: Eyewire News

03.02.20

Novartis Provides Update on Use and Safety of Beovu in Patients With Wet AMD

Source: Novartis

02.25.20

Novartis Responds to ASRS Note Raising Safety Concerns With Wet AMD Drug Beovu

Source: Eyewire News

02.25.20

Novartis Launches Review Into Safety of Eye Drug Beovu

Source: Reuters

12.27.19

Novartis Receives Permanent J-code for Beovu

Source: Novartis

12.16.19

Novartis Receives Positive CHMP Opinion for Beovu (Brolucizumab) for the Treatment of Wet AMD

Source: Novartis

10.08.19

Novartis Receives FDA Approval for Beovu for Wet AMD

Source: Novartis

View more stories